J Psychopharmacol:英国精神障碍医疗成本调查

2013-08-06 wangrui cmt

近期,《精神药理学杂志》(Journal of Psychopharmacology)在线版收录的一篇研究报告的结果显示,随着社会人口的老龄化,脑部疾病在英国的患病率及相应的医疗成本或会不断增加。转化神经科学研究有助于提高治疗的有效性,但目前缺乏足够的资金支持。研究人员指出,解决脑部疾病所面临的临床及经济挑战,需要欧盟整体和国家间的协同合作。 本研究为提高社会对精神疾病和

近期,《精神药理学杂志》(Journal of Psychopharmacology)在线版收录的一篇研究报告的结果显示,随着社会人口的老龄化,脑部疾病在英国的患病率及相应的医疗成本或会不断增加。转化神经科学研究有助于提高治疗的有效性,但目前缺乏足够的资金支持。研究人员指出,解决脑部疾病所面临的临床及经济挑战,需要欧盟整体和国家间的协同合作。

本研究为提高社会对精神疾病和神经功能障碍患病率和医疗成本的关注度,对一项欧洲流行病学资料、患病率和各类障碍的疾病成本的系统回顾中有关英国常见的18种脑部疾病的资料进行总结。

英国共计有4500万脑部疾病病例,每年耗费1340亿英镑。以头痛、焦虑障碍、睡眠障碍、情绪障碍和躯体化障碍最为普遍。花费最多的五类分别为:痴呆:221亿6400万;精神病性障碍:167亿1700万;情绪障碍:192亿3800万;成瘾:117亿1900万。除精神疾病外,此五类疾病的直接医疗费用在总体排名中垫底(小于30亿)。疾病成本大致可分解为:50%的间接成本,25%的直接非医疗及25%的直接医疗成本。 

Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, Joyce E, Rowe J, Wellsted D, Nutt D, Sahakian BJ.The size, burden and cost of disorders of the brain in the UK.J Psychopharmacol. 2013 Jul 25. [Epub ahead of print]

PMID:
23884863

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908157, encodeId=d6d8190815e5a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 07 04:02:00 CST 2014, time=2014-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995885, encodeId=aaeb19958859e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 26 20:02:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787135, encodeId=ac9a1e871357c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 14 03:02:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788147, encodeId=769c1e881476c, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Apr 27 03:02:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908157, encodeId=d6d8190815e5a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 07 04:02:00 CST 2014, time=2014-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995885, encodeId=aaeb19958859e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 26 20:02:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787135, encodeId=ac9a1e871357c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 14 03:02:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788147, encodeId=769c1e881476c, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Apr 27 03:02:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-02-26 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908157, encodeId=d6d8190815e5a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 07 04:02:00 CST 2014, time=2014-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995885, encodeId=aaeb19958859e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 26 20:02:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787135, encodeId=ac9a1e871357c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 14 03:02:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788147, encodeId=769c1e881476c, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Apr 27 03:02:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-05-14 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908157, encodeId=d6d8190815e5a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 07 04:02:00 CST 2014, time=2014-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995885, encodeId=aaeb19958859e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Feb 26 20:02:00 CST 2014, time=2014-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787135, encodeId=ac9a1e871357c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 14 03:02:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788147, encodeId=769c1e881476c, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Apr 27 03:02:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]

相关资讯

Neurobiol Learn Mem:激素水平或有助于认识女性精神障碍性疾病

处于月经期这样一种特殊状态下的女性可能更易感与应激相关的精神疾患。该项研究结果提示每月的时间窗可能成为潜在的治疗靶点用来预防在女性患者中常见的精神健康问题。本研究首次揭开了精神疾患易感性和生理周期(本项研究为月经周期)之间的潜在联系。 情绪和焦虑问题的一个常见症状是有反复出现不必要想法的倾向。这些扰人的思想通常出现于经历压 力后的数天到数周后。在该项研究中,研究者测试了经历紧张后的反应是否与月经

DSM-5因缺乏有效性在美遭冷遇

       本月即将出版的第五版《精神疾病诊断和统计手册》(DSM-5)在付印之前就失去了一个重要顾客。美国国立心理健康研究所(NIMH)所长Thomas Insel日前在其博客上公开宣布,NIMH将不再使用该手册指导其研究。        为了取代该手册,目前NIMH正致力于制定一个长期计划,以开发新的诊断标准和

BMJ:促排卵后出生的孩子精神障碍风险高

丹麦学者的一项研究显示,与自然怀孕出生的孩子相比,经过促排卵/宫腔内人工授精后出生的孩子精神障碍发生率略高,经过体外受精/胞浆内单精子注射出生的孩子总体风险更高。相关论文2013年7月5日在线发表于《英国医学杂志》(BMJ)。 该回顾性队列研究纳入1995-2003年期间出生在丹麦的儿童,随访到2012年,儿童为8-17岁时。其中33 139个孩子通过辅助生殖技术出生,其他555 828个孩子自

左旋肉碱减肥药致精神障碍一例

1、病例 患者,女性,13岁,因疑被人议论伴凭空闻语2d入院。于入院前6d服用减肥药(主要成分左旋肉碱)1粒/d,连服4d,最后1天因把药含在口中过久导致胶囊融化,自己又补服了1粒。之后出现夜间入睡困难,伴早醒。停药1d 后,上课时突然感觉班上的同学在议论她,用奇怪的眼神看她,评论她的打扮和穿着。看到远处的同学讲话,耳边就能听见他们在说:“你看她搽了腮红,太爱漂亮了;头发后面短了一点,以后要秃顶